ReviewVirology journal2017
Hepatitis delta: virological and clinical aspects.
Review in Virology journal, 2017. The graph could read no effect estimate from its abstract, so it casts no vote on the map. It is linked to trial NCT06264583 (Euro-HDV), which is not on this map. Cited by 57 papers, 2 of them syntheses that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Euro-HDV:Epidemiology and Clinical Course in Patients With HIV and Hepatitis B/D -Coinfection
Who cites it
57 citing papers in PubMed, 2 syntheses or guidelines pooled it, 124 citations in OpenAlex.
- The global prevalence of hepatitis D virus infection: Systematic review and meta-analysis.Journal of hepatology · 2020Pooled it
- The Epidemiology of Hepatitis D Virus in North Africa: A Systematic Review and Meta-Analysis.TheScientificWorldJournal · 2018Pooled it
- Characterising Hepatitis D Virus in the UK From 2011 to 2021.Journal of viral hepatitis · 2026Article
- Comprehensive Analysis of Mutations in the Hepatitis Delta Virus Genome Based on Full-Length Sequencing in Individuals Infected with Genotype 3 in Brazil.Archives of virology · 2026Article
- Molecular Characterization of Hepatitis Delta Virus in the Western Amazon, Acre, Brazil.Viruses · 2026Article
- Article
- Towards HDV Elimination Through HBV Vaccination: Global Strategies, Challenges, and Policy Gaps.Vaccines · 2026Review
- Hepatitis D virus infection prevalence in persons with human immunodeficiency virus and hepatitis B virus coinfection in Germany.Infection · 2026Article
- Novel epitope-based diagnostic probes selected by phage display for the serological detection of HDVMemorias do Instituto Oswaldo Cruz · 2026Article
- Human and pathogen-encoded circular RNAs in viral infections: insights into functions and therapeutic opportunities.Human molecular genetics · 2025Review
- Host Immune Response in Chronic Hepatitis Delta: Implications for Pathogenesis and Therapy.Pathogens (Basel, Switzerland) · 2025Review
- Article
- BicyclicInternational journal of molecular sciences · 2025Article
- Global, regional, and national burden of acute hepatitis (1990-2021): a systematic analysis of the global burden of disease in 2021.Frontiers in medicine · 2025Article
- Clinical Evaluation of the Progression of Liver Disease in Patients Coinfected With HBV and HDV in the Western Amazon Region of Brazil.International journal of hepatology · 2025Article
- Molecular Epidemiology of Hepatitis D Virus in the North-East Region of Romania.Pathogens (Basel, Switzerland) · 2024Article
- Improving Access to Anti-HDV Testing: Development and Validation of an Affordable In-House ELISA Assay.ACS omega · 2024Article
- Molecular genetic association of rs8099917 and rs1800795 polymorphisms in the progression of hepatitis Delta virus liver disease.The journal of venomous animals and toxins including tropical diseases · 2024Article
- [Delta hepatitis in Africa: epidemiological and clinical particularities].Medecine tropicale et sante internationale · 2023Review
- Non-Invasive Prediction Scores for Hepatitis B Virus- and Hepatitis D Virus-Infected Patients-A Cohort from the North-Eastern Part of Romania.Microorganisms · 2023Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors at 3 institutions in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
There are an estimated 400 million chronic carriers of HBV worldwide; between 15 and 20 million have serological evidence of exposure to HDV. Traditionally, regions with high rates of endemicity are central and northern Africa, the Amazon Basin, eastern Europe and the Mediterranean, the Middle East and parts of Asia. There are two types of HDV/HBV infection which are differentiated by the previous status infection by HBV for the individual. Individuals with acute HBV infection contaminated by HDV is an HDV/HBV co-infection, while individuals with chronic HBV infection contaminated by HDV represent an HDV/HBV super-infection. The appropriate treatment for chronic hepatitis delta is still widely discussed since it does not have an effective drug. Alpha interferon is currently the only licensed therapy for the treatment of chronic hepatitis D. The most widely used drug is pegylated interferon but only approximately 25% of patients maintain a sustained viral response after 1 year of treatment. The best marker of therapeutic success would be the clearance of HBsAg, but this data is rare in clinical practice. Therefore, the best way to predict a sustained virologic response is the maintenance of undetectable HDV RNA levels.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.